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 Urinary Tract Infections (UTI) are among the most common diagnoses in primary care, 
hospitals, and extended care facilities.  UTIs account for the use of 6 billon health care dollars in 
treatment and management, and cause 8 million patient visits, ultimately resu ting in over 
100,000 hospitalizations per annum (Drekonja, and Johnson. 2008; Stamm 2001).  In over 80% of 
UTIs, the causative agent is a strain of uropathogenic Escherichia coli (UPEC; Chassin et al., 
2006; Mulvey, 2000).  Drug resistant bacterial strains have added to the complications of UTIs, 
resulting in increased frequency of recurrent UTIs (Blanogo, 2010; Drekonja and Johnson, 2008).  
Originating in the colon, these especially virulent uropathogens express adhesive proteins such as 
P pilli, Type 1 pilli, and Dr adhesins which mediate adherence to the epithelial cell surface.  
Specifically, Dr fimbriae are associated with a 2 fold increased risk of recurrent UTIs.  Invasion 
of the cell by UPECs containing Dr fimbriae (Dr+ E. coli) have been shown to cause chronic 
pyelonephritis in the C3H/HeJ mouse model (Kaul et al., 1999; Foxman, et al., 1995; Nowicki et 
al., 2001).  
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 Dr fimbriae bind to uroepithelial cells of the urinary tract through recognition of decay 
acceleration factor (DAF), also known as complement regulatory protein, CD55 (Nowicki 2001).  
DAF, a membrane associated glycoprotein, interacts with Type IV collagen, which is a 
colonization receptor.  This interaction facilitates the invasion of Dr+ E.coli into the cell, causing 
the infection and inflammation observed in UTIs.  Previous experiments in our lab have 
demonstrated that this interaction is hormonally regulated (Selverangan, 2004; Singh et al., 2010)   
 Association with Toll like receptor 4 (TLR) is essential for the initiation of host responses 
due to invasion of the cell by UPECs.  TLR4 binds to lipopolysaccharide (LPS) of the gram 
negative UPECs and is therefore activated to stimulate the production of pro-inflammatory 
cytokines (Vandewalle, 2008).   
 UTIs can affect both men and women; however, they are more prevalent in f males.  
Approximately 50% of adult women report experiencing one or more UTI per annum and some 
women develop a history of repeated infections (Drekonja, and Johnson, 2008).  One of the most 
significant clinical issues of UTIs is recurrence, the mechanism of which is only partially 
understood.  The incidence of UTIs in females is contingent upon age and stage of menstrual 
cycle.  In particular, postmenopausal women demonstrate drastic decreases in estrogen and 
maintain high incidences of UTIs.  This observation, coupled with the fact that UTI occurrence 
varies with stage of menstrual cycle, suggests hormonal regulation (Curran et al., 2007, Straub 
2007).  
 Clinical trials using estrogen hormone-replacement therapy have demonstrated decreased 
incidence in UTIs in postmenopausal women and established estrogen-replacem nt guidelines for 
the prevention of UTI (Dwyer, 2002).  Although, there are studies suggestin  that estrogen 
increases the risk of UTI (Orander, 1992; Curran et al., 2007).  It is widely agreed that estrogen 
has a significant role in protection against infection (Styrt, 1991).  Estrogen may act on the host, 
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the pathogen, or the host-pathogen system as a means of mediating immunity.  Estrogen has a 
wide range of action, via estrogen receptor (ER) α or ER β to regulate gene transcription (Straub, 
2007).  In the kidney, the predominant receptor subtype is ERα (Jelinsky et al., 2003).  Although 
it has been established that estrogen exerts both pro-inflammatory and anti-i flammatory effects 
during pathogenesis, one of the crucial ways in which estrogen regulates the immune system is 
via pro-inflammatory proteins (Fahey, 2008).   
 Tumor Necrosis Factor alpha (TNF-α) is an instrumental factor in mounting the innate 
and adaptive immune response and is one of the most important cytokines in resolvi g UTI 
pathogenesis.  Estrogen effects on TNF-α have been extensively studied.  In vitro studies suggest 
that estrogen suppresses the production of TNF-α in numerous cell types and pathologies 
(Lambert, 2004).  However, estrogen-mediated TNF-α production is increased in acute 
pyelonephritic UTIs (Gϋrgoze et al., 2005).  This speaks to the dichotomous and cell-specific 
action of TNF-α, and demands further inquiry into the mechanism of action.   
 UTIs are a far reaching significant clinical problem forwhich treatment options are 
poorly understood.  Estrogen-mediated protection against UTIs represents a plausible option for 
patient treatment.  As a result, we have developed an in vitro model of the ascending UTI using 
murine inner medullary collecting duct cells of the kidney (mIMCD-3).  We hypothesize estrogen 
modulates Dr+E.coli invasion in mIMCD3 cells by regulating TNF-α production and affecting 
expression of DAF.  Therefore, the current study was conducted to investigate the role of 
estrogen in modulating TNF-α response during Dr+E.coli infection in mIMCD-3 cells.  The long 
term goal of this study is to identify and characterize the cellular and molecular mechanisms 
through which estrogen or estrogen receptors may be modulating the onset and severity of UTIs.  
This information will contribute to the understanding of UTI pathogenesis and the identification 





REVIEW OF LETERATURE 
Urinary Tract Infections 
 It is estimated that 150 million UTIs occur globally per annum, resulting in more than 6 
million dollars of indirect health care expenditure (Stamm, 2001).  In the Unit d States, UTIs 
account for 8 million patient visits per year, 1 million of which are emrgency department visits.  
Collectively, these visits incur billions of dollars for management, and result in over 100,000 
hospitalizations.  The incidence of UTIs occurs predominantly among women, demonstrated by 
the fact that nearly 1 in 3 women will be diagnosed and require antimicrobial therapy by the age 
of 24 years (Foxman, 2003).  Additionally, the prevalence of UTIs in the female population varies 
with age and menstrual cycle, confirming the possibility of hormonal control via estrogen 
(Sobieszczyk, 2008). 
 UTIs may involve either the lower urinary tract, or both upper and lower urinary tract 
(Figure 1).  The term cystitis describes infection in the lower urinary tract and presents as dysuria 
and suprapubic tenderness with urinary frequency and urgency (Nicolle, 2008).  Pyelonephritis 
describes urinary tract infection ascending toward the kidney.  It is a more severe diagnosis, 
presenting with dysuria, abdominal pain and often systemic symptoms including, but not limited 
to, fever, rigors, headache, vomiting and delirium (Ramakrishnan, 2005). 




Figure 1: Location of upper and lower urinary tract infection.  Adapted from 
Supplementnews.org/progressive health.com.   
 
Uropathogenic E.coli 
 Organisms that cause UTIs are derived primarily from the aerobic members of the fecal 
flora.  95% of uncomplicated cases of cystitis are caused by a single organism.  In contrast, 
infections among hospitalized patients or those with structural abnormalities of the urinary tract 
derive from polymicrobial infections (Sobieszczyk, 2008).  
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 The most common causative agent of UTIs are gram negative rods, 80% of which are 
members of  the especially virulent family of Uropathogenic E.coli (UPEC)  The majority of 
these uropathogens originate in the colon, invade the urethra, ascend to the bladder and then to 
the kidney.  As UPECs invade the upper urinary tract in an ascending infectio , they first come 
into contact with the cells of the inner medullary collecting duct (IMCD) in the kidney (Chassin 
et al., 2006, Mulvey, 2002).  Despite the fact that most all strains of E.c li can result in UTI, 
UPEC’s are particularly virulent because of their ability to produce adhesive proteins on their cell 
surfaces called pilli, fimbriae, or adhesins.  These proteins include P pilli, Type 1 pilli, and Dr 
adhesins, which mediate the adherence of bacterium to the cell lining of the bladder and upper 
urinary tract.  P fimbriae (Figure 2) are associated with acute pyelonephritis, and initiate ceramide 
release and activation of signaling pathways (Wult et al.,2000).  They require toll like receptor-4 
(TLR-4) for binding and function, and elicit a strong proinflamatory respon e to 
lipopolysaccharide (LPS) challenge.  (Hellund, 2001; Johnson, 1991).  E.coli Type 1 fimbriae are 
associated with cystitis and mediate bladder cell invasion.  Type 1 fimbriae require cluster of 
differentiation 14/ TLR4 (CD14/TLR4) interaction and signaling and cause the production of 
interleukin 6 (IL-6) via a LPS- dependent pathway (Curran, 2007).  Of particul  interest, E.coli 
Dr fimbriae are associated with increased risk of recurrent UTI and h ve been proven to cause 
experimental chronic pyelonephhritis (Goluszko et al., 1997; Goluszko et al., 2001; Nowicki et 
al., 2001).  The E.coli Dr fimbriae adhesin was originally cloned from the clinical pyelonephritis 
strain, E. coli IH11128. Biogenesis of Dr fimbriae requires the draA gene as well as three others 
(draC, draD, draE) (Norwicki, 2001).  Dr adhesins of Dr+ E.coli have been shown to be essential 
for the induction of chronic pyelonephritis in the C3H/HeJ mouse model (Goluszk  et al., 1997; 
Nowicki et al 2001) They invade the uroepithelium using lipid rafts and microtubule networks 
and subsequently bind to the cells of the uroepithelium via recognition of type IV collagen and 





Figure 2: Escherichia coli demonstrating fimbriae  Image adapted from Dennis 
Kunkel Microscopy, Inc. 
  









 DAF is a glycosyl-phosphatidyl-inositol protein bound to the cell membrane by a region 
of four consecutive extracellular short consensus repeats (SCR).  The physiological function of 
DAF is to protect the host cell from the cytotoxic effects of complement activation.  DAF has a 
wide tissue distribution, which includes epithelial surfaces of the gastrointestinal mucosa, 
exocrine glands, renal pelvis, ureter, bladder, cervix, and uterine mucosa.  In the human 
endometrial epithelium, DAF expression is dynamically regulated through the reproductive cycle, 
demonstrated by an increase in expression during pregnancy (Hasan, 2002; Fang, 004; 
Selvarangan, 2004, Nowicki, et al., 1990, Nowicki et al., 1993; Lui, 2004, Mulvey, 2002).  Dr+ 
E. coli recognizes DAF to adhere, invade, and colonize the kidney epithelium, and further binds 
to type IV collagen in the epithelial basement membrane (Selvarangan, 2004).    
 Interaction of Dr+ E.coli with DAF and type IV collagen in the kidney leads to bacterial 
infection, inducing inflammation in renal tubules.  Type IV collagen is found on the basement 
membrane of the renal interstitial cells and is a specialized form of extrac llular matrix that 
underlies all epithelia and compartmentalized tissues.  The adherence of bacteria to type IV 
collagen in the basement membrane of the epithelium facilitates renal p rsistence of Dr+ E.coli 
and the development of pyelonephritis (Selverangan, 2004).   
 The adherence of UPECs to the uroepithelium induces an inflammatory response via 
pathogen-specific virulence factors.  The uroepithelium forms a physical barrier against 
microorganisms, which complements the passive shield of antimicrobial proteins.  These proteins 
respond to invasion by activating immune cascades (Jahnukainen, 2003).  Briefly, the 
inflammatory response progresses in three steps.  First, bacteria simulate uroepithelial cells to 
produce pro-inflammatory mediators.  Second, these chemokines and their chemokine receptors 
direct inflammatory cells to the site of infection.  Third, the local inflammatory response 







Figure 3: Mechanism of UPEC invasion in host cells during Dr+ E.coli uropathogenesis.      
I.  Attachment of  Dr+ E. coli to DAF receptors on the apical surface of the epithelial membrane, 
resulting in bacterial colonization; II.   DAF receptor clustering on the membrane and 
internalization by the phagocytic pathway due to the redistribution of cyt skeleton-associated 
factors and microtubules; initiation of internalization; III .  Bacterial internalization into a vacuole 
within the host cell and attachment to type IV collagen in the basement membrane.  Image 










UTI and Inflammation 
 Activation of the innate immune response in the urinary tract is dependent on the 
recognition of the UPEC pathogen-associated molecular patterns by pattern recognition receptors.  
UPEC pathogen-associated molecular pattern includes LPS, flagella, type 1 pilli, and  P pilli that 
can act through TLR and nucleotide binding and oligomerization domain-like receptors (Rudick 
et al., 2010; Zhang et al., 2004; Fahey, 2008).  The recognition of molecular patterns displayed 
on the surface of UPEC microorganisms by TLRs, and their subsequent activa ion, leads to the 
transcription of appropriate host-defense genes (Zhang et al., 2004).  TLRs play a vital part in the 
recognition of bacterial machinery.  The renal tubule and epithelial cells express TLR 1, 2, 3, 4, 6 
and 11.  TLR 4 recognizes LPS, the main constituent of Gram-negative E.coli, and is a crucial 
interaction in mounting an immune response.  TLR 11, expressed in mouse kidney an  bladder 
epithelial cells (not in humans), is thought to aid in the recognition of UPEC pathogens 
(Vandewalle, 2008).  Studies have demonstrated that UPECs invading the kidney specifically 
bind to the apical surface of collecting duct cells.  The signaling pathways th t are activated by 
UPECs in the collecting duct cells of LPS-sensitive C3H/HeOuJ and LPS-defective C3H/HeJ 
mice show that UPECs stimulate expression of pro-inflammatory mediators n the medullary 
collecting ducts via TLR4 pathways as a result of the activation of TNF (Vandewalle, 2008, 
Chassin et al., 2007).    
 The UPEC-induced inflammatory response is a result of tissue damage caused by cell 
apoptosis, as well as neutrophil and macrophage activation.  As reported by Rudick et al., (2010),  
the local production of inflammatory chemokines results in the rapid recruitment of neutrophils 
into the bladder lumen, which in turn mediates bacterial clearance. The most potent of the local 
pro-inflammatory chemokines and cytokines implicated in the elicited response include, Il-6, IL-
1β, IL-8, TNF-α, Nf-κB and others (Gϋrgoze, 2005) 
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UTI and pro-inflammatory cytokine, TNF- α 
 Of the pro-inflammatory cytokines that control the response to UPECs, TNF-α is 
particularly important (Figure 4).  Originally described as an agent of death in relation to tumor 
cells (Georgiadou, 2009), TNF-α is a cytokine with a host of actions.  TNF-α is produced 
primarily by macrophages and other mononuclear phagocytes in the kidney (Ferrri, 2007).  
Although monocytes and macrophages are the main source of TNF-α, the local production of the 
cytokine stimulated by intrinsic renal cells is of greater significance in renal inflammation 
(Ernandez, 2009).  TNF-α is known to stimulate chemokines and adhesion molecules, induce 
apoptosis, and activate the microbial system of phagocytes.  TNF-α is implicated in renal 
inflammation and glomerular damage induced by immune complex deposition, as renal 










Figure 4: Intracellular signaling pathways induced by TNF-α.  TNF-α induces the 
trimerization of the TNF receptor on the cell surface which causes the recruitment of adapter 
molecules to the receptor.  The adaptor molecule-receptor complex pathways leads to activation 
of caspase 8 and apoptosis (the death pathway) or the activation of gene transcription factors AP-





 Additionally, TNF-α activates the transcription factor NF-κB, which has been described 
as the master switch of the immune system (Male, 2006).  Metcalfe et . states that TNF-α is 
capable of up-regulating its own expression, in addition to that of other inflammatory mediators, 
as it induces renal fibrosis and apoptosis (Figure 4).  Gene polymorphisms influence TNF-α 
production and inflammatory responses of the uroepithelium to UPEC challenge.  Polymorphisms 
of the TLR gene are responsible for the delayed clearance of bacteria from the urinary tract, as 
well as the hyporesponsiveness to LPS and the resulting predisposition to septic shock 
(Jahnukainen 2005).  
 The excessive release of TNF-α may cause tissue damage as seen in LPS-induced renal 
failure due to TLR-4 mediated production of TNF-α.  In contrast, blocking TNF-α improves renal 
function, while simultaneously aggravating the renal bacterial burden in experimental mouse 
models of renal failure.  These findings speak further to the role of pro-inflammatory cytokines 
such as TNF-α in an immune response (Vandewalle, 2008).  Importantly, levels of pro-
inflammatory cytokines including TNF-α were increased in acute pyelonephritic UTIs, compared 
to levels in lower UTIs (Gϋrgoze et al., 2005).   
 In kidney disease, experimental data suggest that TNF-α exhibits both pro-inflammatory 
and immunosuppressive functions.  These roles are relayed by two structurally distinct receptors, 
TNF-receptor 1(R1) and TNFR2.  These receptors are only 28% homologous in theirex racellular 
domain, and share no homology of intracellular regions (MacEwan, 2002).  TNFR2 has a higher 
affinity for membrane bound TNF.  Studies conducted by Ernandez in 2009  implicated TNFR2 
in mediating inflammation in renal injury.  Finally, considering that the colle ting duct is the 
main site of adhesion for UPECs it is likely that hormones involved in controlling sodium and 
water reabsorption, particularly those that act in the collecting duct, could be involved in 




Estrogen the immunomodulator 
 Sex steroids play an important role during the inflammatory response by influenceing 
injury-induced cytokine production (Metcalfe, 2006).  Estrogen is a steroid hormone which plays 
a vital role in reproduction, growth, development, and maintenance of numerous tissues.  The 
physiological effects of estrogens are mediated through one of two estrogen recepto s (ER), ERα 
and ERβ, both of which belong to the superfamily of nuclear receptors.  ERs integrate multiple 
signals from ligands and intracellular signaling pathways to perform functions in the nucleus and 
cytosol (Moggs, 2001).  ERα and ERβ are products of different genes and elicit tissue and cell 
type specific estrogen-mediated activity.  Additionally, each receptor has different transcriptional 
activities in certain ligand, cell type, or promoter contexts (Mathews, 2003). The ligand binding 
domains of each receptor exhibit an affinity for endogenous estrogen, 17β-estradiol (E2).  
However, ERα and ERβ demonstrate different affinities for some natural compounds, as well as 
for novel subtype-specific ligands, demonstrating that the ERs are similar, but  maintain unique 
roles in estrogen actions (Kuiper, 1997, Mathews, 2003).  ERα localizes on the uterus, liver, 
kidney and heart, while ERβ is expressed primarily on the ovary, prostate, lung, gastrointestinal 
tract, bladder, and hematopoietic and central nervous system.  Both recepto  subtypes are co-
expressed in numerous tissues; however, both may not be expressed in the same c ll type 
(Kuiper, 1997)  
 ER complexes affect gene expression through two main pathways, the classic genomic 
pathway and the non-genomic pathway.  The classic pathway depends on direct interaction of 
estrogen with its receptor in the nucleus.  These ER complexes then can directly mediate gene 
transcription.  The action of ERα and ERβ are mediated by two transcription activation functions 
(AFs).  AF-1 is the N-terminal ligand-independent activation function and AF-2 is the C-terminal 
15 
 
ligand-dependent activation function.  These AFs mediate transcription and cell-promoter 
specificity (Nilssson et al., 2001).  The non-classical, non-genomic pathway is a rapid interaction 
that is dependent on the ability of estrogen to interact with steroid or non-ster id hormone 




Estrogen mediated regulation of inflammation and inflammatory markers 
 Sex steroids in both in vivo and in vitro experimental models have been shown to 
influence immune function and inflammatory processes, although the mechanisms are poorly 
understood (Czlonkowska, 2005).  Estrogens have both anti-inflammatory and pro-inflammatory 
functions.  For instance, E2 enhances the production of proinflamatory interferon-γ and anti-
inflammatory IL-10 in T cells (Fahey, JV 2008, Correale, 1998, Calabrese, 2001  Straub, 2007) 
ER-bound up or down-regulates the transcription of various genes by binding to estrogen 
response elements (EREs) of genes, or through interaction with transcription factors (Beato, 
1989, Paech, et al 1997, Straub 2007).  There is well documented evidence that post-menopausal 
women experience an increase in pro-inflammatory cytokines, as estrogen decr ases (Kovas, 
2005).  However, estrogen has paradoxical effects on the immune system.  The paradoxic l 
immunomodulatory effect of estrogen is contingent on a number of factors.  These factors include 
the source of immune stimulus, cell type involved during various phases of disease, the target 
organ, the stage of menstral cycle, the physiological concentration of estrogen, the variability of 
ER expression (which, in turn, varies with microenvironment and cell type), intracellular 
metabolism of estrogens, pro-inflammatory function, and the influence of s nsory and 
sympathetic nervous systems (Straub, 2007). 
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 The contention that estrogen regulates the immune system is supported by in vivo studies, 
in which protective functions fluctuate with the stage of the menstrual cycle (Straub, 2007).  
Additionally, numerous cytokines, chemokines and antimicrobials present in cervical-vaginal 
lavage vary with stage of menstrual cycle, whether measurements wre taken during the early 
proliferative or late secretory phase of the menstrual cycle (Figure 5).  Pro-inflammatory cytokine 
production varies with circulating levels of estrogen in females during pregnancy and menopause.  
For instance, the concentration of IL-8 and defensins are lowest at mid-cycle when ovulation 
occurs and E2 levels are elevated (Fahey, 2008).  Studies have shown that high-dose estrogen 
treatment of C3H/HeJ mice resulted in increased bacterial infection rates in the kidney, regardless 
of the adhesin type ( Stamm, 2007).  Further studies have shown that estrogen can enhance the 
attachment of UPECs, challenging the claim that estrogen treatment is always protective (Curran, 
2007).  
 Estrogen also functions as an immunomodulator by regulating the levels of IgG and IgA 
antibodies, which also are altered by the stage of the menstrual cycle.  Immunoglobulins in 
human cervical mucus increase over the days leading up to ovulation and then decline to their 
lowest levels at other stages in the cycle (Beagley, 2003)  Similarly, estrogen diminishes cell-
mediated immunity in humans and rodents, demonstrated by the decrease in levels of natural 
killer (NK) cell activity in females compared to males.  The activity of NK cells also decreases 
from the first to third trimester of pregnancy as estrogen levels demonstrate drastic concentration 
changes (Styrt 1991).     
 Finally, estrogen regulates immunity by suppressing or enhancing the expr ssion of pro-
inflammatory mediators; however, estrogen-mediated inflammatory disease is as a result of 





Figure 5: Demonstration of the pro-inflammatory and anti-inflammatory effects of estrogen 
on varying immune cell types throughout reproductive life.  Various cell types demonstrate 
that at pregnancy levels, E2 effects on important pro-inflammatory pathways are inhibited.  The 
orange color demonstrates the inhibition of TNF, IL-1β, IL-6, MCP-1, iNOS, production of 
MMPs, and the activity of natural killer cells.  E2 at the same concentration stimulates anti-
inflammatory effects such as Il-4, IL-10, TGFβ, TIMP and osteoprotegrin delineated by green.  
At lower E2 concentrations, E2 stimulates of TNF, IFN-γ, IL-1β and natural killer cell activity.  









 TNF-α participates in innate immunity and adaptive immune responses. As a result of 
receptors present on virtually all cells, TNF-α is able to elicit diverse effects, including activating 
a variety of genes (Ferreri, 2006)  Although TNF-α production is tightly regulated, this cytokine 
is widely reported to be elevated in postmenopausal women and ovariectomized (OVX) rats.  
This finding is consistent with in vitro experiments, and demonstrates the possibility of hormonal 
control of TNF-α production (Arenas, 2005; Kamada, 2001; Sites, 2002; Ferreri 2007; Metcalfe, 
2006; Xing 2007; Huang, 2008).   
 The estrogen regulation of TNF-α has been extensively studied in numerous tissue types 
and pathologies.  Estrogen demonstrates both up-regulation and down-regulation of TNF-α 
expression in various tissues in response to various agents of injury.  For instance, E2 treatment 
causes profound up-regulation of TNF-α expression in the small intestine following trauma-
hemorrhage (Chen, 2008), in human uterine epithelial cells following challenge by TLR3 agonist 
Poly(I:C) (Schaefer, 2005), in three week old mice challenged with oxazolone (OXA), a chemical 
allergen to the flank (Sakazaki, 2008), and in a renal ischemia/reperfusion model in rats (Wolfs, 
2002).  In contrast, E2 treatment also causes profound down-regulation of TNF-α expression as 
seen in vascular smooth muscle cells (Xing, 2007), in glial cells as a result of Alzheimer’s disease 
pathology (Valles, 2009), in the dura due to spinal injury (Cuzzocrea, 2007), and in periodontal 
ligaments following LPS challenge.    
  Epidemiological and immunological evidence suggest that estrogen plays an important 
role in modulating bacterial invasion, susceptibility, and inflammation by mediating TNF-α 
expression and bacterial adherence (Ernandez and Mayadas, 2009, Mulvey, 2002).  However, 
increased estrogen levels in pregnancy and decreased estrogen levels at menopause both enhance 
susceptibility to UTIs.  Moreover, young women capable of reproducing have physiological 
levels of estrogen which play a vital role in decreased susceptibility to UTIs.  Long term 
treatment with estrogen causes adverse effects in some groups (Straub, 2007).  Additionally, 
TNF-α demonstrates pro-inflammatory and anti-inflammatory function in response t  infection 
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(Ernandez and Mayadas, 2009).  These conflicting findings make it difficult to predict the 
immunosuppressive effect of treatment with TNF- α or anti- TNF-α (which may lead to sepsis or 
autoimmunity).  Therefore, it is necessary to further investigate the effects of estrogen on UTI 
susceptibility, invasion, and cytokine modulation at physiological levels.  A better understanding 
of the role of E2 in regulating TNF-α during UTI pathogenesis may lead to novel means of 

















RESEARCH DESIGN AND METHODOLOGY 
Experimental cell line 
  The terminal inner medullary collecting duct (IMCD) serves a crucial role in the 
pathophysiological progression of a Urinary Tract Infection (UTI).  he present study makes use 
of polarized epithelial murine IMCD-3 cell line ( mIMCD-3) (ATCC CRL-2123TM).  This cell 
line was derived from the individual tubules of the terminal IMCD of mice transgenic for the 
early region of SV40 [Tg(SV40E)bri/7] (Rauchman et al., 1993).  This cell line, a gift from Dr. 
Hari Koul (University of Colorado at Denver and Health Science Center, Denver, CO), retains 
numerous characteristics of the terminal nephron segment.  These characteristic include, but are 
not restricted to, high transepithelial resistance, inhibition of apical-to- basal sodium flux by 
amiloride, as well as the ability to grow in hypertonic medium comm n to the kidney medulla 
and lethal to most cell types (Rauchman et al., 1993).  The collecting duct system is the main site 
of adhesion of UPECs and, therefore, ideal for the investigation of experimental UTI 
(Vandewalle, 2008)   
 In the current experiments, Dr+ Escherichia coli strain IH11128 (O75;K5;H-) was 
utilized to generate a model of an inflammatory UTI in mIMCD-3 cells  to investigate the 
resulting uropathogenesis and the  immunomodulatory effects of estrogen on TNF-α.  
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mIMCD-3 Cell Culture 
 mIMCD-3 cells were cultured in Dulbecco’s modified Eagle Medium nutrien  mixture  F-
12 (DMEM-F12; Invitrogen/Gibco) and supplemented with 10% fetal bovine serum (FBS; 
Atlanta Biologicals).  Additionally, 100 U/ml penicillin and 100 µg/ml streptomycin (Invitrogen) 
were added.  The resulting confluent outgrowth of cells was observed on the surface of a T-25 
cm2 or T-75 cm2 cell culture flask.  Cells were then subcultured at a 1:4 ratio via trypsinization 
with 0.05% Trypsin, 0.053 mM EDTA (1X; Trypsin/EDTA) to attain 80-90% confluent 
monolayer.  The culture monolayer was maintained in a 37°C humidified atmosphere (95%) 
containing 5% CO2.  
 Initially, the mIMCD-3 cells were washed with 3-5 ml (depending on flask size) Ca
+ and 
Mg+ free phosphate buffered saline (PBS) by gently rocking the flask for 30 seconds.  The media 
was discarded and replaced with 2-3 ml of Trypsin/EDTA, and rocking was resumed for another 
10 seconds.  The trypsin-EDTA solution was discarded and the flask returned to the humidified 
atmosphere within the incubator as described above, for 10 minutes.  DMEM-F12 media 
supplemented with 10% FBS and antibiotics (3 ml to 6 ml) was added to the cultur  flasks.  After 
gentle agitation via pipette, the cell mixture was divided into two flasks.  An additional 4.5 ml or 
9.0 ml of DMEM-F12 media supplemented with 10% FBS and antibiotics was added to each T-









Drug treatment of mIMCD-3 cells prior to bacterial invasion 
 In preparation for drug treatment, mIMCD-3 cells were washed with PBS.  Surviving 
cells were counted via a haemocytometer and plated in 12-well plates at a density of 0.6 x 106  
cells/ml/well.  mIMCD-3 cells were cultured in medium contai ing DMEM-F12, 100 U/ml 
penicillin, 100 µg/ml streptomycin, and 5% charcoal stripped  FBS (VWR).  The cells were 
returned to incubation for 18 to 24 hours to allow for growth and adherence to the pla e surface, 
after which the cell monolayer was treated with various drugs.  Specifically, the mIMCD-3 cell 
monolayer was treated with 10 nM E2 (Sigma-Aldrich) or co-treated with 10 nM E2 and 10 µM 
ICI 182,780 (Tocris Bioscience).  Drug compounds were diluted to desired concentrations by 
adding serum free media.  In the same vein, control conditions were established by adding serum 
free media and omitting drugs.  The cells were then returned to a 37°C humidified atmosphere 
containing 5% CO2 for 24 hours prior to the introduction of Dr 
+ E. coli strain IH11128  
Induction of UTI in mIMCD-3 cells 
Dr + E. coli strain IH11128 (O75;K5;H-) was received from Dr. Bogdan Nowicki (University of 
Texas Medical Branch at Galveston, Texas).  The pure culture was maintained in our laboratory 
under cryoprotective conditions at -80 ° C.  Dr + E. coli strain IH11128 is a clinical isolate 
obtained from a female patient diagnosed with asymptomatic pyelonephritis (Nowicki, 1996) and 
has previously been used to induce uropathogenic inflammation (Kaul et al., 1999; Curran, 2007).  
 
 Induction of experimental UTI  in mIMCD-3 cells was accomplished by the introducing 
fresh Dr+ E.coli  isolates in suspension as previously described (Kaul et al., 1999).  Several loops 
of bacterial inocula grown overnight at 37°C on Luria agar  (LA) plates were suspended in sterile, 
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serum-free, antibiotic-free DMEM-F12 media; the optical density of the bacterial suspension was 
0.5 at 600 nm.  
 The mIMCD-3cell monolayer was overlaid with 100 µl of Dr+ E. coli in suspension, and 
an equal volume of treated (10nM E2, 10nM E2 and 10µM ICI 182 780) or untreated medium 
added to each well.  The simulated cell invasion and infection was allowed t  proceed by 
incubating for 2 or 8 hours, in the previous humidified environment.  External bacteria were then 
removed by two washes with sterile PBS. 
Two hour infection bacterial invasion   
 After 2 hours, plates were removed from the humidified environment.  The supernatant 
was collected for ELISA studies and stored in a cryo-protective en ironment at -80°C.  The cell 
monolayer was harvested for RNA isolation and subsequent quantitative real time reverse 
transcriptase-polymerase chain reaction (RT-PCR).   
8 hour bacterial infection invasion   
 A second group of plates was removed from the humidified environment after 2 hours.  
Supernatant containing extracellular Dr+ E. coli bacteria was removed and collected for ELISA 
studies, this was done to minimize the possibility of increase in bacterial c ll division that could 
artificially increase the bacterial count of the supernatant at 8 hours.  These plates were then 
returned to humidified incubation for an additional 6 hours.  Collected supernatant, harvested 2 
hours and 8 hours post infection were stored in a cryo-protective environment at -80°C and used 
for ELISA studies.  The cell monolayer was harvested for RNA isolation and subsequent 





.  RNA isolation and cDNA synthesis 
 i) Homogenization of cell extracts 
 Total RNA isolation was accomplished via the use of Trizol reagent (Invi rogen) as 
instructed by the manufacturer.  The cells were lysed directly in the 12 well culture plate by 
adding of 333 µl of Trizol reagent and passing the cell lysate through a pipette tip repeatedly. 
Finally, the lysate was added to separate labeled sample tubes.  
 ii) Phase separation of cell lysate 
 Homogenized mIMCD-3 cells were incubated for 5 minutes at room temperature to 
disassociate nuclear proteins, after which 200 µl of chloroform was added to the cells.  The 
sample tubes were then agitated vigorously for 15 seconds followed by centrifugation at a 
maximum of 12,000 g for 15 minutes at 4° C.  After centrifugation, the homogenized cell lysate 
separates into two layers, an upper colorless aqueous phase and a lower red phenol chloroform 
phase.  The aqueous phase retains RNA and was transferred 100 µl at a time into separate RNAse 
free tubes until the entire volume from each sample tube was transferred.      
 iii)RNA precipitation 
 700µL of isopropyl alcohol was added to each RNAse free aqueous phase-containing  
tube.  The samples were incubated at 30°C for 10 minutes, then centrifuged at 12,000 g (4° C) for 







 iv) RNA washing and re-dissolving   
 The isopropyl alcohol-containing supernatant was removed and the pellet then was 
washed with 75% ethanol (12.5 ml of RNase-free water and 37.5 ml of ethanol).  Up to 1000 µl 
of 75% ethanol was added to the pellet and mixed by way of vortex and centrifugation at 8,000 
Xg for 5 minutes at 4° C, after which the supernatant was discarded.  1000 µl of 75% ethanol was 
again added to the pellet and mixed by way of vortex and centrifugation at 8,000 Xg for 7 
minutes at 4° C.  Ultimately, final remnants of supernatant were carefully removed by pipetting.   
  After washing, the pellet was allowed to dry completely for 20-30 minutes by ventilating 
and inverting sample tubes.   
 RNA was re-dissolved in 50 µl of RNase-free.  Solution was passed through a pipette tip 












vi) RNA quantization and Integrity verification 
   RNA was quantified using NanoDrop spectrophotometer technology as per the 
manufacturer’s instructions (ND-1000 V 3.3.1).  The ratio of absorbance at 260 nm and 280 nm is 
used to assess the purity of DNA and RNA. Additionally, the 260 nm : 230 nm ratio of 
absorbance is a secondary measure of nucleic purity.  Values for the 260/280 ratio and 260/230 
ratio should be approximately 2.00, with values of 1.8-2.0 accepted for either ratio Values outside 
of the acceptable range suggested protein contamination were corrected by RNA purification with 
RNAeasy Mini Kit (Qiagen).     
 RNA integrity was verified on 1% Agarose (Invitrogen) denaturing gel.  NorthernMax 
Gly 10X gel prep/ running buffer (Ambicon), Millenium marker and Glyoxal Sample load Dye 
(Ambicon) were used.  1µg quantities of RNA were loaded onto the agarose gel to ensure proper 
visualization.   
 
 vii) DNase Treatment and cDNA Synthesis 
  DNase treatment was performed on 10 µg of RNA with 2U of enzyme in a 50 µl system 
following kit instructions (Ambicon).  EDTA was employed to stop the reaction via the chelation 
of metals. 
 cDNA synthesis employed the total RNA from each sample, which underwent rev rse 
transcription.  Our lab makes use of high capacity cDNA kit.  Manufacturer provided 2X reverse 
transcription master mix was constituted from the contents of the hig  capacity cDNA kit.   RNA 
samples were then added, and the mixture placed in a thermal cycle (Tabl 1) to perform cDNA 




Quantitative real-time Reverse Transcriptase–polymerase chain reaction (real-time RT-
PCR) 
  Quantitative RT-PCR is a technique that provides amplified DNA for the detection of 
relative or absolute DNA content.  RT-PCR is driven by a polymerase enzyme and is dependent 
on thermal cycling which, in turn, controls primer binding and polymerase activity 
(http://www.primerdesign.co.uk).  Fluorescing dyes that bind to double stranded DNA are used to 
monitor PCR in real time.  In our lab, fluorescing SYBR green serves as a detector for cycle 
threshold (Ct).  SYBR green is a fluorogenic minor groove binding dye which binds to double 
stranded DNA formed in PCR, thereby quantifying it.      
 An ABI StepOne Real Time PCR System (Applied Biosystems) was used to perform real 
time PCR.  PCR was conducted using the following cycle parameters: holding stage- 95° C for 10 
min (1 cycle), then 95 ° C for15 sec, 60° C for 1minute ( 40 cycles); Melt curve- 95°C  for15 sec, 
60 ° C , 95° C for 15 sec (1 cycle).  SYBR green chemistry was used to obtain dat  from the 
cDNA samples introduced into the system using Power SYBR green master mix (Promega), Go 
Taq qPCR  master mix (Promega) and cDNA templates.  TNF-α and DAF gene expression were 
measured (Table 1).  Primers were received from realtimepris.com in 50 µM concentrations 
and were then reconstituted to a working dilution of 1 µM.  Primers contained forward and 
reverse primers in each sample.  The internal control was an endogenous primer, Peptidylprolyl 
Isomerase A (PPIA), which allowed us to normalize the mRNA target to total RNA, thereby 
correcting for differences in the amount of total RNA.      
 Samples were run in duplicate with a hot start.  A melt curve was performed and each 
sample was quantified using SYBR green quantitative PCR machines and chemistry.  The total 
content of double stranded DNA in each well at each cycle produced the Ct value.  
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 PCR data from each treatment group was analyzed based on values normalized to the 
measured expression of PPIA.  Ct values were calculated based on the normalized values.  Values 
were calculated as ∆Ct= Ct target-Ct PPIA and via interpretation of relative gene expression data 
(RQ) calculated as follows; 2-∆CT.  Mean RQ values for each sample group were used for 

















Table 1: Primers for real-time RT-PCR (realtimeprimers.com) 









NM_010016 247bp 246-492 
PPIA Fp:AGCTCTGAGCACTGGAGAGA 
Rp: GCCAGGACCTGTATGCTTTA 
AK028210 178bp 155-332 
TNF-α Fp: CCCACTCTGACCCCTTTACT 
Rp:TTTGAGTCCTTGATGGTGGT 











Quantitative Enzyme Linked Immunosorbent Assay (ELISA) 
 TNF-α protein present in each treatment group was detected and quantified using mouse 
TNF-α ELISA Ready-SET-Go! Kits from eBiosicence.  Kits contain capture antibody, polyclonal 
detection antibody, Avidin enzyme, assay diluent, substrate,  ELISPOT coating buffer,  and 
standard in the form of Recombinant TNF-α (1 ug/ml).  The standard curve range was 8-1000 
pg/ml. Plates were read via spectrophotometer and recorded with softmaxPro software.  
Statistical Analysis 
 The data collected from all experiments were analyzed with GraphPad Prism 4 software.   
One way ANOVAs was followed by Tukey’s post hoc testing when significat effects were 
found.  P-values less than 0.05 were taken as indicative of statistical significance.  









TNF-α mRNA expression in β-estradiol (E2) treated mIMCD-3 cells after 2 hours of 
infection with Dr+ E. coli   
 These experiments were conducted to determine the role of E2 in the regulation of TNF-α 
mRNA expression during Dr+ E.coli bacterial infection in mIMCD-3 cells 2 hours post infection 
(Figure 6).  One way ANOVA revealed a significant effects  [F (4,29) = 97.44, p < 0.001].  TNF-
α expression in uninfected cells with E2 treatment was not different from uninfected control cells 
that received vehicle-treatment alone.  Dr+ E.coli infection in mIMCD-3 cells for 2 hours induced 
TNF-α mRNA levels that were significantly increased when compared with uninfected untreated 
control cells as well as uninfected E2 treated cells.  Further, Dr+ E.coli infected mIMCD-3 cells 
that received E2 treatment showed enhanced TNF-α mRNA expression.  We observed 
specifically, cytokine mRNA levels were significantly increased when compared with both 
untreated or E2 treated cells without infection, as well as with untreated Dr+ E. coli infected cells 
(Figure 6).  Dr+ E.coli infected mIMCD-3 cells that were co-treated with E2 and the ER 
antagonist ICI 182, 780, showed significant reduction in TNF-α mRNA, and thus, reversal of 
TNF-α mRNA increase that was observed in infected cells treated with E2 alone.  H wever, 
TNF-α mRNA levels were comparable in E2 and ICI co-treated cells and in cells with Dr+ E.coli 





























































Figure 6: TNF-α mRNA expression in mIMCD-3 cells treated with E2 or with E2 and ICI 
followed by infection with Dr+ E. coli for 2 hours.  TNF-α mRNA levels were analyzed by 
quantitative SYBR green real-time RT-PCR and expressed relative to th housekeeping gene, 
PPIA.  Uninfected and infected mIMCD-3 cells were treated with either 10 nM E2 or co-treated 
with 10 nM E2 and 10 µM ICI.  Untreated cells and 10 nM E2 treated cells without infection 
served as controls.  Error bars are representative of data from 3 experiments, performed in 
quadruplicate.  One-way ANOVA revealed a significant main effect [F(4,29) = 97.44, p < 0.001]; 
this was further examined using Tukey’s post hoc testing.  ##, indicates significant difference 
relative to untreated control (Control), ■  indicates significant difference relative to  E2–treated, 
uninfected control (E2), ∆ indicates significant difference relative to untreated infected ells (Dr+ 




TNF-α mRNA expression in E2 treated mIMCD-3 cells after 8 hours of infection with Dr+ 
E. coli   
 These experiments were conducted to determine the role of E2 in the regulation of TNF-α 
mRNA expression during Dr+ E.coli bacterial infection in mIMCD-3 cells at 8 hours post 
infection (Figure 7). One way ANOVA revealed significant main effects [F(4,33) = 11.41, p < 
0.001].  TNF-α expression in uninfected cells with E2 treatment was not different from 
uninfected control cells that received vehicle-treatment alone.  Dr+ E.coli infection in mIMCD-3 
cells for 8 hours increased in cytokine mRNA levels; however, TNF-α mRNA was not 
significantly different when compared with control or E2-treated cells without infection.  E2 
treatment enhanced TNF-α mRNA expression in infected cells.  Specifically, cytokine mRNA 
levels were significantly increased when compared with control or E2 treated cells without 
infection, and cells with Dr+ E. coli infection alone (Figure 7).  Co-treatment with E2 and ICI in 
infected cells also increased TNF-α mRNA levels when compared to control cells receiving either 
vehicle treatment or E2 treatment alone, as well as, to those infected with Dr+ E.coli.  However, 
























































Figure 7: TNF-α mRNA expression in mIMCD-3 cells treated with E2 or with E2 and ICI 
followed by infection with Dr+ E. coli for 8 hours.  TNF-α mRNA levels were analyzed by 
quantitative SYBR green real-time RT-PCR and expressed relative to PPIA.  Uninfected and 
infected mIMCD-3 cells were treated with either 10 nM E2 or co-treated with 10 nM E2 and 10 
µM ICI.  Untreated cells and 10 nM E2 treated cells without infection served as controls.  Error 
bars are representative of data from 3 experiments, performed in quadruplicate.  One-way 
ANOVA revealed significant main effects [F (4,33) = 11.41, p < 0.001].  This was further 
examined using Tukey’s post hoc testing.  ##  indicates significant differenc  relative to untreated 
control (Control),  ■  indicates significant difference relative to E2–treated, uninfected control 






TNF-α protein expression in E2 treated mIMCD-3 cells after 2 hours of infection with Dr+ 
E. coli 
 These experiments were conducted to determine the role of E2 in the regulation of TNF-α 
protein expression during Dr+ E.coli bacterial infection in mIMCD-3 cells after 2 hours (Figure 
8).  One way ANOVA revealed significant main effects [F(4,14) = 8.022, p < 0.01].  TNF-α 
expression in uninfected cells pretreated with E2 did not differ from uninfected control cells that 
received vehicle-treatment alone.  Dr+ E.coli infection in mIMCD-3 cells for 2 hours induced 
protein levels that were significantly increased when compared with untreated control and with 
E2-treated control cells without infection.  E2 treatment of Dr+E.coli infected cells tended to 
decrease TNF-α protein levels when compared to Dr+ E.coli infected cells without treatment; 
however, the groups were not statistically different.  TNF-α protein levels in E2-treated infected 
cells were increased when compared with E2-treated cells without infection (Figure 8)    
Dr+ E.coli infected mIMCD-3 cells that received E2 and ICI co-treatment showed a decrease in 
TNF-α protein levels when compared with infected cells with or without E2 treatm nt.  
Moreover, in TNF-α protein levels were significantly less than those in infected cells.   
















































Figure 8: TNF-α protein expression in mIMCD-3 cells treated with E2 or with E2 and ICI 
followed by infection with Dr+ E. coli for 2 hours.  TNF-α protein levels were analyzed by 
ELISA.  Uninfected and infected mIMCD-3 cells were treated with either 10 nM E2 or co-treated 
with 10 nM E2and 10 µM ICI.  Untreated cells and 10 nM E2-treated cells without infection 
served as controls.  Error bars are representative of data from 3 experiments, performed in 
quadruplicate.  One-way ANOVA revealed significant main effects[F(4,14) = 8.022, p < 0.01]. 
This was further examined using Tukey’s post hoc testing.  ## indicates difference relative to 
untreated control, ■ indicates significant difference relative to E2-treated, uninfected control 






TNF-α protein expression in mIMCD-3 cells after 8 hours infection with Dr+  
E. coli 
 These experiments were conducted to determine the role of E2 in the regulation of TNF-α 
protein expression. 
 In mIMCD-3 cells infected with Dr+ E.coli for 8 hours there were no differences among 
the various treatment groups (Figure 9).  Thus, the levels of TNF-α protein were comparable in 
all experimental groups at this time point.  
 
   
   


















































Figure 9: TNF-α protein expression in mIMCD-3 cells treated with E2 or with E2 and ICI 
followed by infection with Dr+ E. coli for 8 hours.  TNF-α protein levels were analyzed by 
ELISA.  Uninfected and infected mIMCD-3 cells were treated with either 10 nM E2 or co-treated 
with 10 nM E2 and 10 µM ICI.  Untreated cells and 10 nM E2 treated cells infected with Dr+ 
E.coli served as controls.  Error bars are representative of data from 3 experiments, performed in 








DAF mRNA expression in E2 treated mIMCD-3 cells after 2 hour infection with Dr+ E. coli.  
 These experiments were conducted to determine the role of E2 in the regulation of DAF 
mRNA expression during Dr+ E.coli bacterial infection in mIMCD-3 cells 2 hours after infection 
(Figure 10).  DAF mRNA expression was somewhat variable 2 hours post infection with Dr+ 
E.coli.  Infected cells pretreated with E2 appeared to reduced DAF mRNA expression ven 
though there was no significant difference.  






























































Figure 10: DAF mRNA expression in mIMCD-3 cells treated with E2 or with E2 and ICI 
followed by infection with Dr+ E. coli for 2 hours.  DAF mRNA levels were analyzed by 
quantitative SYBR green real-time RT-PCR and expressed relative to housekeeping gene, PPIA.  
Uninfected and infected mIMCD-3 cells were treated with either 10 nM E2 or co-treated with 10 
nM E2 and 10 µM ICI.  Untreated cells and 10 nM E2 treated cells without infection served as 
controls.  Error bars are representative of data from 2 experiments, performed in quadruplicate.  







DAF mRNA expression in E2 treated mIMCD-3 cells after 8 hour infection with Dr+ E. coli.  
 These experiments were conducted to determine the role of E2 in the regulation of DAF 
mRNA expression during Dr+ E.coli bacterial infection in mIMCD-3 cells at 8 hours post 
infection (Figure 11).  One way ANOVA reveled significant main events [F(4,18) = 0. 4954].  
DAF expression in infected cells pretreated with E2 showed reduction in DAF when compared to 
uninfected control cells that received vehicle treatment alone and infected cells co-treated with E2 
and ICI but not significantly when compared with untreated infected cells.  Thus, E2 and ICI co-
treatment significantly reversed the reduction of DAF mRNA levels seen in E2 treated Dr+ E.coli 



































































Figure 11: DAF mRNA expression in mIMCD-3 cells treated with E2 or with E2 and ICI 
followed by infection with Dr+ E. coli for 8 hours.  DAF mRNA levels were analyzed by 
quantitative SYBR green real-time RT-PCR and expressed relative to housekeeping gene, PPIA.  
Uninfected and infected mIMCD-3 cells were treated with either 10 nM E2 or co-treated with 10 
nM E2 and 10 µM ICI.  Untreated cells and 10 nM E2 treated cells without infectio  served as 
controls.  Error bars are representative of data from 2 experiments, performed in quadruplicate.  
One-way ANOVA revealed a significant main effects [F(4,18) = 0. 4954] that were further 
examined using Tukey’s post hoc testing.  ## indicates significant difference relative to untreated 
control (Control), ×:  indicates significant difference relative to infected, E2-treated cells (Dr+ 







SUMMARY AND CONCLUSIONS 
  
 The underlying mechanism of UTI pathogenesis is only partially understood.  Despite 
numerous studies in humans and experimental animals which demonstrate the importance of 
UPEC virulence factors, host defense mechanisms, and the likelihood of h rmonal control, the 
exact mechanism of UTI pathogenesis remains elusive.  From a clinical perspective, the 
recommended use of estrogen in the prevention of UTI has been only for postmenopausal women 
who are not receiving oral estrogen and have > 3 recurring UTIs per year (Stamm, 2007).  This 
negates a large population of patients who suffer from UTI.  This untreated population, mostly 
comprised of women, includes pregnant women, of whom 27% have been found to undergo 
premature labor attributed to inflammation with Dr+ E.coli (Kaul et al., 1991; Millar, 1997).  
This pathological condition, due to its far reaching effects in the population, demands 
investigation into estradiol’s effects during UTI pathogenesis.   
 In recent studies conducted in an established model of UTI in mIMCD-3 cells, w  
observed that E2 differentially modulates Dr+ E.coli invasion of mIMCD-3 cells in a dose 
dependent manner (Singh, et al, 2010).  Specifically, physiological doses of E2 (10nM) 
significantly decreased bacterial invasion, compared to the cells treated with pharmacological 
doses of E2 (100nM) or to cells receiving vehicle treatment (Singh et al, 2010) .   
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 Additionally, this in vitro model of UTI also demonstrated that co-treatment of mIMCD-
3 cells with E2 and ICI reversed the E2 protection against of Dr+ E.coli invasion in mIMCD-3 
cells, suggesting ER involvement.   
 Based on these findings, the current experiments were conducted in this established in 
vitro model of UTI using 10nm E2 as a means of studying E2 effects on TNF-α production and 
DAF expression in kidney inner medullary collecting duct cells.   
 At the onset of infection due to UPEC in the bladder or kidney, epithelial cells stimulate 
the production of pro-inflammatory cytokines and chemokines such as IL-6, IL-8, IL-1β, and 
TNF-α, NF-κB and others.  Of these cytokines, TNF-α is a key player in mounting a response to 
infection and is largely implicated in renal inflammation and glomerular damage.  TNF-α is 
known to activate chemokines and adhesion molecules, induce apoptosis, and activ te the 
microbial system of phagocytes (Ernandez, 2009).  The E2 mediated regulation of TNF-α has 
been studied in numerous tissues types and pathologies.  It is shown to be up-regulated in both 
mouse and human kidney infections (Ernandez, 2009; Fahey, 2008).   
 Under the current experimental conditions, E2 treatment in uninfected mIMCD-3 cells 
did not give any conclusive data at mRNA or protein levels for TNF-α.  This may be attributed to 
our research design.  Uninfected mIMCD-3 cells require additional incubation time points or 
testing with varying E2 doses to reveal E2 modulation of TNF-α expression.  Alternately, absent 
infection with E2 may not affect TNF-α levels.  
 In Dr+ E. coli infected mIMCD-3 cells with or without E2 treatment, we observed 
increased TNF-α production at mRNA levels 2 hour after infection.  In fact, TNF-α mRNA levels 
in untreated mIMCD-3 cells infected with Dr+ E. coli tended to be increased at both time points.  
E2 treated, Dr+ E.coli infected mIMCD-3 cells, further increased TNF-α mRNA levels.  Based on 
these data, our findings suggest that E2 provides protection against bacterial invasion by up-
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regulating TNF-α expression at the message level during the course of infection at 2 hour as well 
as at 8 hour post infection.  Czlonkowska et l report that mRNA levels of pro-inflammatory 
cytokines are regulated by natural changes in estrogen concentration; however, this ability may 
vary with tissue.  Studies by Agace (1993) using an in vitro model of UTI in kidney and bladder 
cells, reported that challenge with E.coli bacteria, activates pro-inflammatory cytokine 
production.  Their studies showed that there is a selective cytokine production by epithelial cells 
following exposure to E.coli 
 To confirm ER involvement in E2 modulation of TNF-α mRNA, mIMCD-3 cells were 
co-treated with E2 and ICI.  E2 co-treatment with ICI inhibited the up-regulation of TNF-α 
mRNA 2 hours after infection with Dr+ E.coli; suggesting that E2-mediated protective effects 
against Dr+ E.coli invasion in mIMCD-3 cells occurs via ER activity.  This finding of ER 
involvement in the protection against invasion agrees with our previous in vitro UTI studies 
(Singh et al., 2010).  ICI is a pure ER antagonist and may down-regulate ERα which is the major 
ER in the kidney.  This strongly suggests that E2-mediated modulation of TNF-α in mIMCD-3 
cells infected with Dr+ E.coli is ER dependent and possibly occurs through ERα (Kuiper et al 
1997).    
 It is unclear why the ICI effect occurred primarily at the 2 hour time point.  One 
possibility is that the continued increase in TNF-α mRNA occurs by a different mechanism that 
may be independent of ERs.  Alternatively, it may be that the ICI concentration we used was 
insufficient to prevent the E2 effect 8 hours after infection.  
 Under the experimental conditions of the current study, TNF-α protein levels displayed 
much variability in infected mIMCD-3 cells, both 2 hours and 8 hours post infect on.  Dr+ E. coli 
infected cells showed increased TNF-α protein levels only after 2 hours of infection.  By 8 hours, 
TNF-α protein levels were comparable in all treatment groups.  
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 Surprisingly, E2 treatment tended to decrease TNF-α protein levels in cells infected with 
Dr+ E.coli for 2 hours compared to Dr+ E.coli infected cells without E2.  Additionally, co-
treatment of mIMCD-3 cells with E2 and ICI further enhanced the decrease.  mIMCD-3 cells 
infected with Dr+ E.coli for 8 hours showed no differences among treatment groups in these 
experimental conditions, which may suggest that secreted TNF-α protein levels may have peaked  
just prior to the 8 hour infection time point.  However, the fact that TNF-α was elevated 8 hours 
after infection argues against this interpretation.   
 The variability seen in TNF-α protein data was seen in 7 replicate experiments, only 3 of 
which are reported here.  This variability in TNF-α protein data may be attributed to a number of 
experimental or technical factors which require further refinement to allow for firm conclusions.  
Firstly, consideration of the multiplicity of infection (MOI); that is the ratio infectious agents 
adjusted to number of seeded cells.  Secondly, the sensitivity and loss of receptor function in 
mIMCD-3 cells sub cultured more than 4 times (note: mIMCD-3 cells were received at passages 
15-20) and additional E2 dose and infection time point need further testing.  Finally, one 
important consideration is that the TNF-α protein measured represents secreted protein.  
Verification using techniques other than ELISA are therefore critical.  The examination of protein 
levels using techniques such as FACS analysis, immunocytochemistry, Western blotting, and 
confocal microscopy will allow us to assess TNF-α protein localized in the cell.   
 DAF functions as a major player in host defense against bacterial invasion by regulating 
the complement system on the membrane.  Interaction of UPECs with DAF is the primary 
method of adherence, invasion, and colonization of kidney epithelium (Selvarangan, 2004). In 
previous studies, our lab, and others observed that DAF expression is hormonally regulated in 
uroepithelial cells.  (Hasan, 2002; Fang, L. 2004; Selvarangan, 2004, Nowicki et al., 1993; Lui, 
2004, Mulvey, 2002). 
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 We evaluated infected mIMCD-3 cells at 2 and 8 hour time points to observe th  effect of 
E2 treatment at physiological levels and to ascertain its effects on DAF mRNA in mIMCD-3 
cells.  Treatment of Dr+ E.coli infected mIMCD-3 cells with physiological levels of E2 decreased 
DAF mRNA expression only after 8 hours.  The apparent decrease after 2 hours was not 
significant suggesting further refinement of experimental parameters may be advantageous.  In 
any case, TNF-α mRNA levels appeared to be inversely regulated in relation to DAF mRNA 
levels.  These findings are consistent with previous studies in which pysiological levels of E2 
were observed to down-regulate DAF expression in mIMCD-3 cells and to decrease bacterial 
invasion (Singh et al., 2010).  To confirm ER involvement in E2 modulation of DAF, mIMCD-3 
cells were co-treated with E2 and ICI.  Our findings demonstrate that co-treatment of Dr+ E.coli 
infected mIMCD-3 cells with E2 and ICI significantly reversed the decrease in DAF mRNA 
levels observed at 8 hours post infection, suggesting ER involvement.   
 In summary, these data suggest that E2-mediated protective effects against Dr+ E.coli 
invasion in mIMCD-3 cells, occurs via up-regulation of TNF-α and simultaneous down-
regulation of DAF mRNA.  In vitro models show that Dr + E.coli adhesion factors recognize and 
adhere to DAF in order to invade and colonize the kidney epithelium which leads to inflammation 
(Selvarangan et al, 2004; Mulvey, 2002).  Our studies suggest that E2 treatment elicits protective 
effects in Dr+ E.coli infected mIMCD-3 cells by reducing DAF expression on cells, and thereby 
reducing bacterial invasion.   
 As per our hypothesis ,estrogen modulates Dr+E.coli invasion in mIMCD3 cells by 
regulating TNF-α production and affecting expression of DAF.  Our current observations of TNF-
α mRNA production at 2 and 8 hour time points, as well as DAF mRNA at the 8 hour time point 
support our hypothesis 
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 Finally, our observations also suggest that E2-affects TNF-α and DAF mRNA expression 
via ER pathways.  This finding is supported by Straub (2007) who suggested tha  that estrogen 
levels up-regulate or down-regulate TNF-α expression in a cell type specific manner.  
 Detailed studies are required, to clarify the modulatory effects of E2 in Dr+ E. coli UTI  
uropathogenesis in kidney IMDCs, and its influence on TNF-α and DAF expression.  This would 
require experiments directly investigating the effects of recombinant TNF-α in mIMCD-3 cells 
and a further understanding the role of TNF and well as TNF-receptors in E2 modulation of UTIs.  
Similarly, blocking action of TNF-α by using antibodies in in vitro models, or alternatively, using 
TNF-α knock-out mice will provide further insight into the mechanisms of E2 control of TNF-α 
during UTIs.  The information gained by these studies will lead to the identification of novel 
biomarkers for the treatment of UTIs.  
 Further studies are needed to confirm our observations by utilizing additional techniques.  
These studies will allow us to better understand the mechanism of interaction between host 
receptor and bacterial ligand, and will aid in the development of novel therapeutics to treat the 
incidence of UTIs.  Recent studies demonstrate implications of TNF-α in UTIs.  TNF-α 
polymorphisms in children with UTIs show renal scarring, demonstrating the effect of TNF-α in 
the kidney (Savvidou, 2010).  Thus, pre-clinical studies are needed to explore the possible 
benefits of TNF-α therapy in chronic UTIs. 
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